Full Press Release Details
Access the “What This Means” segment here
LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) --GRI Bio, Inc.(NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in aVirtual Investor “What This Means” segment.
As part of the segment,Marc Hertz, PhD, President, Chief Executive Officer and Directorof GRI Bio, discussed important insights from the Company’srecently reported additional positive Phase 2a datain Idiopathic Pulmonary Fibrosis (IPF), including a series of compelling biomarker results that demonstrate improvements in key drivers of fibrosis and lung repair.
The “What This Means” segment can be accessedhere.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an RARβγ agonist shown to inhibit the activity of key immune cells, like iNKT cell activity, and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775GRI@jtcir.com